Interchangeability of vaccines

Pediatric Infectious Disease Journal

Volumn 20, Issue 11 SUPPL., 2001, Pages

  Feldman, S ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Diphtheria tetanus toxoids acellular pertussis vaccine; Haemophilus influenzae type b vaccine; Hepatitis B vaccine; Interchangeability; Poliovirus vaccine; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B INACTIVATED POLIOMYELITIS VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED POLIOMYELITIS VACCINE; IPOL; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; TRIPACEL; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BORDETELLA PERTUSSIS; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SCREENING; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE COST; HEALTH PROGRAM; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SEROLOGY; VIRUS INFECTION;

DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; PEDIATRICS; PERTUSSIS VACCINE; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; VACCINATION; VACCINES, COMBINED;

EID: 0035158981     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200111001-00004     Document Type: Article

References (35)

1. Combination vaccines for childhood immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP)
2. Pertussis vaccination: Use of acellular pertussis vaccines among infants, and young children - Recommendations of the Advisory Committee on Immunization Practices (ACIP)
3. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
4. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
5. Efficacy of a two-component acellular pertussis vaccine in infants
6. Efficacy of acellular pertussis vaccine in early childhood after household exposure
7. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
8. Pertussis vaccine
9. Evaluation of the interchangeability of two different diphtheria -tetanus-acellular pertussis (DTPa) vaccines administered to healthy infants at 2, 4 and 6 months of age
10. Immunogenicity of acellular pertussis vaccines using two vaccines for primary immunization
11. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children
12. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children
13. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTPa) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine
14. Hepatitis B vaccine
15. Antibody responses of healthy neonates to two mixed regimens of hepatitis B vaccine
16. Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another
17. Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP)
18. Prevention of poliomyelitis: Recommendations for use of only inactivated poliovirus vaccine for routine immunization
19. Apparent global interruption of wild poliovirus type 2 transmission
20. Notice to readers: Recommended childhood immunization schedule - United States, 2000
21. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses
22. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines
23. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules
24. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine
25. A randomized study of the safety and immunogenicity of DTPa-HB-IPV vaccine administered as three doses or in a sequential IPV/OPV schedule at 2, 4, and 6 months of age
26. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants
27. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants
28. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: Evaluation of a two-dose mixed regimen
29. Inter-changeability of conjugated Haemophilus influenzae type b vaccines during primary immunisation of infants
30. Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines